1. New ISPOR Good Practices Task Force Reports
   1. In February, Value in Health published a  “A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force. The report is accompanied by the ISPOR Roadmap for Patient Preferences in Decision Making, which consists of 5 key elements: (1) context, (2) purpose, (3) population, (4) method, and (5) impact.
      
      The report also includes a set of guiding questions for those conducting or appraising patient-preference studies across each of the 5 elements. The ISPOR Roadmap is methods agnostic and will aid researchers and improve studies regardless of the preference method used.   The report was accompanied by an editorial,  “Navigating Patient-Preferences Studies for Cross-Stakeholder Decision Making: A Roadmap Guides the Way”.  For more information, the press release is available here.

       

   2. A new Good Practices Report from the ISPOR Quantitative Benefit-Risk Assessment in Medical Product Decision Making Task Force was published in the April 2023 issue of Value in Health.  This report provides a set of pragmatic and actionable steps for developing high-quality studies that incorporate explicit decision weights. The report also provides a useful checklist for reporting quantitative benefit-risk assessments. 
      
      The report is accompanied by an editorial, Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Step Forward and a case study, Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis. For more details, please see the press release here.
      
      
2. New Special Interest Group Reports
   1. The ISPOR Health Equity Research Special Interest Group published a new article, titled “The Impact of Digital Health Technologies on Health Equity: Designing Research to Capture Patient-Reported Outcomes” in the January/February 2023 issue of Value & Outcomes Spotlight. This article highlights several important considerations for the healthcare community regarding health equity in patient-reported outcomes and measures (PROs/PROMs) development as well as operability in clinical research and practice.  https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/addressing-assessment-and-access-issues-for-rare-diseases/the-impact-of-digital-health-technologies-on-health-equity-designing-research-to-capture-patient-reported-outcomes
   2. The ISPOR Open-Source Models Special Interest Group published a new paper, titled “The Role of Education in Shaping an Open-Source Future” in the January/February 2023 issue of Value & Outcomes Spotlight. This article focuses on the role of education in developing and using transparent health economic analyses to improve the transparency of health policy decisions, noting how this is not the sole element affecting the transparency of decisions.  https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/addressing-assessment-and-access-issues-for-rare-diseases/the-role-of-education-in-shaping-an-open-source-future
   3. BIOSIMILARS SIG VOS REPORT
      1. The ISPOR Biosimilars Special Interest Group (SIG) published a new article, titled “Opening Up a Discussion on Biosimilar Value Assessment” in the March/April 2023 issue of Value & Outcomes Spotlight. The article reports on the SIG’s 2022 ISPOR EU Forum, where they presented key learnings from their research project and engaged the audience on issues of knowledge gaps and challenges relating to assessing biosimilars value. Two questions were essential to the Forum discussion and are elaborated in the article. These include “what has been and what is the foreseeable role of HTA for biosimilars?” and “should biosimilars value assessment be restricted to a price comparison between the reference biologic and the biosimilar?” To read the article, please follow this link: https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/heor-and-the-future-of-work/opening-up-a-discussion-on-biosimilar-value-assessment  

          

3. ISPOR Reports on Events
   1. A summary of the 2022 ISPOR Payer Summit, titled “Incorporating Different Elements of Value into Technology Assessment”, was published in the March/April 2023 issue of Value & Outcomes Spotlight. This article summarizes the key points of the 2022 ISPOR Payer summit which focused on what value means to different stakeholders and what other definitions of value could one use when making coverage and reimbursement decisions. The 2023 ISPOR Payer Summit will take place on May 7 and will focus on the impact of new legislation in Europe and the US and will also talk about health equity. https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/heor-and-the-future-of-work/incorporating-different-elements-of-value-into-technology-assessment

Recent Events  

1. ISPOR is updating and adding national pharmacoeconomic guidelines to our Pharmacoeconomic Guidelines Around the World resource page. For more information or to submit your country’s guidelines, please email: HEORresources@ispor.org.

Recent Webinars Available for On-Demand Viewing

1. The ISPOR HTA Council recently presented an HEOR Theater, “HTA Implementation in the MEA Region – an Overview From WHO and Country Updates” .
2. The ISPOR Health Preference Research Special Interest Group hosted “Preventing, Detecting, and Analyzing Data from Suspected Fraudulent Respondents in Online Surveys, with Examples from Health Preference Studies”.  The recording is available here.
3. Patient-Centered SIG Patient-Focused Drug Development (PFDD) Guidance Webinar Part 1 of 2 was held February 2
4. Digital Endpoint Adoption: the How, What and Why
5. Preventing, Detecting, and Analyzing Data from Suspected Fraudulent Respondents in Online Surveys, with Examples from Health Preference Studies
6. Improving Treatment Access and Outcomes by Integrating Social Determinants of Health Data With Real-World Evidence
7. The ISPOR Patient-Centered Special Interest Group held Part 2 of its two-part series on the Patient Focused Drug Development (PFDD) Guidances from the FDA. The webinar was held on Tuesday, March 7, 2023 and the recording will be available on the ISPOR Webinars page soon. Part 1 of the series can be viewed here.
8. Introduction to Open-Source Modeling: R We There Yet? 

New Opportunities  

1. ISPOR is encouraging task force proposals on topics within the economic evaluation category of ISPOR’s Science Strategy.  A particular focus is methods of analysis and presentation of heterogeneity in cost-effectiveness or addressing heterogeneity in economic models.  Please review the stated economic evaluation priorities here: https://www.ispor.org/strategic-initiatives/science-strategy or via ISPOR’s Science Strategy via the Strategic Initiatives menu at the top of the ISPOR homepage.

ISPOR Roundtable Updates

The ISPOR Health Technology Assessment Roundtable – Asia Pacific was held on 8 March 2023. 45 attendees from 20 countries/jurisdictions in Asia Pacific met virtually to discuss the assessment of digital health technologies for reimbursement and regulatory approval. For more information on the ISPOR HTA Roundtables, please see here. A webinar based on this HTA Roundtable will take place on 8 June 2023 at 9:00pm EDT. Save your seat here.